Exercise of Warrants
RNS Number : 3993C
11 October 2022
(“Agronomics” or the “Company”)
Exercise of Warrants
Total Voting Rights
Agronomics Limited (AIM:ANIC), a leading listed company focused on cellular agriculture, announces that pursuant to the receipt of notice for the exercise of warrants, it is issuing 3,528 new Ordinary Shares with a nominal value of £0.000001 each in the capital of the Company (“Shares”) at a subscription price of 30.0p per Share, and 3,361 new Shares at a subscription price of 28.5p per Share. The Company has received gross proceeds of £2,016.28.
Application has been made for the 6,889 Shares to be admitted to trading on AIM (“Admission“), with Admission expected to occur on or around 17 October 2022.
The Shares will rank pari passu with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared after the date of their issue.
Following Admission of the Shares, the Company will have 977,985,563 ordinary shares with a nominal value of £0.000001 each in issue with voting rights and admitted to trading on AIM. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 24 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world’s expanding population. A full list of Agronomics’ portfolio companies is available at https://agronomics.im/.
About Cellular Agriculture
Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.
Over the coming decades, the source of the world’s food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement’s goal of limiting warming to 1.5℃
AT Kearney, a global consultancy firm, projects that cultivated meat’s market share will reach 35% by 2040. This combined with the Good Food Institute’s estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world’s protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 4 billion has been invested worldwide since the industry’s inception in 2016.
For further information please contact:
|Agronomics Limited||Beaumont Cornish Limited||Canaccord Genuity Limited||Cenkos Securities Plc||Peterhouse Capital Limited||TB Cardew|
|The Company||Nomad||Joint Broker||Joint Broker||Joint Broker||Public Relations|
|Richard ReedDenham Eke||Roland CornishJames Biddle||Andrew PottsHarry ReesAlex Aylen (Head of Equities)||Giles BallenyMax GouldMichael Johnson||Lucy WilliamsCharles Goodfellow||Ed OrlebarAlistair Walker|
|+44 (0) 1624 email@example.com||+44 (0) 207 628 3396||+44 (0) 207 523 8000||+44 (0) 207 397 8900||+44 (0) 207 469 0936||+44 (0) 20 7930 0777+44 (0) 7738 724 firstname.lastname@example.org|
This information is provided by RNS, the news service of the London Stock Exchange
. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange